Wall Street Zen Upgrades Cyclacel Pharmaceuticals (NASDAQ:BGMS) to Hold

Cyclacel Pharmaceuticals (NASDAQ:BGMS) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Cyclacel Pharmaceuticals Stock Up 10.7%

Cyclacel Pharmaceuticals stock opened at $1.34 on Wednesday.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.